Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Conditions

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Trial Timeline

Sep 11, 2013 → Sep 14, 2016

NCT ID

NCT01922102

About Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT

Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT is a phase 3 stage product being developed by Novartis for Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM). The current trial status is completed. This product is registered under clinical trial identifier NCT01922102. Target conditions include Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM).

What happened to similar drugs?

3 of 8 similar drugs in Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) were approved

Approved (3) Terminated (3) Active (4)

✅Ranibizumab + AfliberceptNovartisApproved

✅RanibizumabNovartisApproved

✅Ranibizumab + AfliberceptNovartisApproved

🔄pudexacianinium chlorideAstellas PharmaPhase 3

🔄RanibizumabNovartisPhase 3

❌Sham injections + Ranibizumab 0.5 mgNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01922102	Phase 3	Completed	Sep 11, 2013	Sep 14, 2016	Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Competing Products

13 competing products in Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

See all competitors

Product	Company	Stage	Hype Score
pudexacianinium chloride	Astellas Pharma	Phase 3	40
pudexacianinium chloride	Astellas Pharma	Phase 3	40
Blink® Tears eye drops + Investigational lipid eye drops	Johnson & Johnson	Phase 1	29
Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper	Johnson & Johnson	Phase 2	35
Ranibizumab	Novartis	Phase 3	40
Ranibizumab + Aflibercept	Novartis	Approved	35
Ranibizumab	Novartis	Approved	43
Sham injections + Ranibizumab 0.5 mg	Novartis	Phase 3	32
Ranibizumab + Dexamethasone implant and sham injections	Novartis	Phase 3	40
Ranibizumab + Aflibercept	Novartis	Approved	35
Intravitreal Lucentis 0.5mg	Novartis	Pre-clinical	22
ZK200775 + ZK200775 + Sodium Chloride	Bayer	Phase 1	26
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)	Bayer	Pre-clinical	27